ViroCell Appoints John A Dawson CBE as Chairman of the Board of Directors
ViroCell Appoints John A Dawson CBE as Chairman of the Board of Directors

ViroCell Biologics (“ViroCell”) today announces the appointment of John A. Dawson CBE as Chairman of the Board of Directors (“Chairman”).

ViroCell aspires to be the global viral vector supplier of choice for novel cell and gene therapy clinical trials. John’s appointment as Chairman further validates the commercial opportunity for ViroCell and represents another major milestone as we build towardsbecoming a global market leader in the viral vector clinical trial CDMO market.

Read More
Florence Buchanan
ViroCell strengthens senior management team with appointment of Nick Maishman as COO
ViroCell strengthens senior management team with appointment of Nick Maishman as COO

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (“COO”).

ViroCell, an innovation-driven Contract Development and Manufacturing Organisation (“CDMO”), is today addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

Read More
In the NewsFlorence Buchananviral vectors, UK CDMO, CDMO, gene therapy, cell therapy, clinical trials, cell and gene therapies, Nick Maishman, ViroCell, Pharmiweb.com
ViroCell Strengthens Senior Management Team with Appointment of Nick Maishman as COO
ViroCell Strengthens Senior Management Team with Appointment of Nick Maishman as COO

ViroCell Biologics, founded by the UK’s most prolific academic viral vector manufacturing team, today announces the appointment of Nick Maishman as Chief Operating Officer (COO).

ViroCell, an innovation-driven Contract Development and Manufacturing Organisation, is today addressing the global viral vector supply-demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene-modified cells for clinical trials. ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.

Read More
In the NewsFlorence BuchananUK CDMO, CDMO, gene therapy, cell therapy, cell and gene therapies, clinical trials, Nick Maishman, Pharmtech Focus, viral vectors
ViroCell names Susan Nichols as CBO
ViroCell names Susan Nichols as CBO

ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO).

The firm is seeking to address the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies by focussing on the design and GMP manufacture of viral vectors…

Read More
In the NewsFlorence BuchananUK CDMO, CDMO, gene therapy, cell therapy, cell and gene therapies, clinical trials, viral vectors, Susan B Nichols, ViroCell, The Pharma Letter
ViroCell Announces the Appointment of Susan B. Nichols as CBO
ViroCell Announces the Appointment of Susan B. Nichols as CBO

ViroCell, an innovation-driven Contract Development and Manufacturing Organization (“CDMO”), is addressing the global viral vector supply demand imbalance that constrains the timely manufacture of novel cell and gene therapies. ViroCell focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.

ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies.

Read More
In the NewsFlorence BuchananUK CDMO, gene therapy, cell therapy, ViroCell, Pharmtech Focus, clinical trials, cell and gene therapies, CDMO, Susan B Nichols, viral vectors
Gene therapy ‘factory’ to save children
Gene therapy ‘factory’ to save children

A new “factory” that will produce benign viruses for Great Ormond Street Hospital is expected to accelerate the development of life-saving gene therapy drugs.

The facility, which is based in the hospital and operated by the biotech company ViroCell Biologics, will more than double Britain’s capacity to manufacture a key type of gene therapy.

Read More
In the NewsFlorence BuchananVirocell BiologicsGOSH, CDMO, Gene and cell therapies, viral vector, cell therapy, gene therapy, The Times, UK CDMO, Great Ormond Street Hospital, ViroCell, John W. Hadden II, Farzin Farzaneh, biotech, Dame Kate Bingham, John Hadden, Rhys Evans, SCID, severe combined immunodeficiency, Professor Claire Booth, leukaemia, spinal muscular atrophy, Leber congenital amaurosis, inherited diseases
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

ViroCell Biologics confirms a new agreement to address the worldwide viral vector market for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Life Sciences Review, UK CDMO, ViroCell, Great Ormond Street Hospital, John W. Hadden II, Farzin Farzaneh, Matthew Shaw
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage
Virocell and Great Ormond Street Hospital team up to tackle viral vector shortage

Great Ormond Street Hospital (GOSH) has partnered with manufacturer ViroCell Biologics in an effort to address the global viral vector manufacturing bottleneck for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, European Pharmaceutical Manufacturer, UK CDMO, ViroCell, Matthew Shaw, CEO at Great Ormond Street Hospital
ViroCell and Great Ormond Street Hospital for Children address viral vector manufacturing bottleneck
ViroCell and Great Ormond Street Hospital for Children address viral vector manufacturing bottleneck

As part of the partnership, ViroCell will more than double the UK’s lentivirus vector manufacturing capacity for clinical trials in 2022 and become the first UK CDMO to be able to deliver AAV vectors to the cell and gene therapy markets.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Health Newest, UK CDMO, John W. Hadden II, Farzin Farzaneh
ViroCell Biologics announces pivotal partnership with Great Ormond Street
ViroCell Biologics announces pivotal partnership with Great Ormond Street

Innovation-driven viral vector manufacturer, ViroCell Biologics, and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH), have announced a new partnership that aims to dislodge the gene and cell therapy bottleneck.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Pharmafile, UK CDMO, Matthew Shaw, CEO at GOSH, Great Ormond Street Hospital
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”
ViroCell Biologics and Great Ormond Street Hospital for Children Announce Partnership to Dislodge Gene and Cell Therapy “Logjam”

ViroCell Biologics (“ViroCell”), founded by the UK’s most prolific academic viral vector manufacturing team, and Great Ormond Street Hospital for Children NHS Foundation Trust (“GOSH”), a world leading children’s hospital, have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Pharmiweb.com, UK CDMO, ViroCell, John W. Hadden II, Farzin Farzaneh, Matthew Shaw, Scientific Advisory Board
ViroCell Biologics and GOSH to address gene and cell therapy “logjam”
ViroCell Biologics and GOSH to address gene and cell therapy “logjam”

ViroCell Biologics and Great Ormond Street Hospital (GOSH) partner to tackle the viral vector manufacturing bottleneck for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, UK CDMO, ViroCell, Great Ormond Street Hospital, European Pharmaceutical Review, EPR
ViroCell Biologics and GOSH to address gene and cell therapy “logjam”
ViroCell Biologics and GOSH to address gene and cell therapy “logjam”

ViroCell Biologics and Great Ormond Street Hospital for Children (GOSH) have today announced a new partnership that will immediately address the global viral vector manufacturing bottleneck for clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, Biopharma Curated, UK CDMO, Great Ormond Street Hospital, Virocell
ViroCell and Great Ormond Street Hospital for Children address viral vector manufacturing bottleneck
ViroCell and Great Ormond Street Hospital for Children address viral vector manufacturing bottleneck

ViroCell Biologics and Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) have formed a new partnership to immediately address the global viral vector manufacturing bottleneck for clinical trials.

Read More
In the NewsFlorence BuchananGOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, gene therapy, cell therapy, BioPharma Reporter
Partners aim to remove clinical trials bottleneck
Partners aim to remove clinical trials bottleneck

Life sciences firm ViroCell Biologics is working in partnership with Great Ormond Street Hospital (GOSH) to help alleviate a major barrier to progress in clinical trials.

Read More
In the NewsFlorence BuchananCDMO, GOSH, Zayed Centre for Research, clean rooms, cell and gene therapies, 1L to 200L batch size, viral vectors, lentivirus vector, AAV vectors, CGT, cell therapy, gene therapy, Health Tech World, UK CDMO, vector design, John W. Hadden II, Farzin Farzaneh